复发性胶质母细胞瘤全身药物治疗的新前景？
A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?
作者信息
Lombardi Giuseppe, Idbaih Ahmed, Le Rhun Emilie, Preusser Matthias, Zagonel Vittorina, French Pim
机构信息
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, via Gattamelata 54, 35128 Padua, Italy.
Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013 Paris, France.
出版信息
Cancers (Basel). 2020 Dec 15;12(12):3775. doi: 10.3390/cancers12123775.
Abstract
Glioblastoma is the most common and aggressive primary malignant brain tumor in adult patients [...].
摘要
胶质母细胞瘤是成年患者中最常见且侵袭性最强的原发性恶性脑肿瘤[……]。
相似文献
1
A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?复发性胶质母细胞瘤全身药物治疗的新前景？
Cancers (Basel). 2020 Dec 15;12(12):3775. doi: 10.3390/cancers12123775.
2
Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework.针对局灶性复发性原发性胶质母细胞瘤的积极重复手术：结果与理论框架
Neurosurg Focus. 2015 Mar;38(3):E11. doi: 10.3171/2014.12.FOCUS14726.
3
Overcoming therapeutic resistance in glioblastoma: the way forward.克服胶质母细胞瘤的治疗耐药性：前进的道路。
J Clin Invest. 2017 Feb 1;127(2):415-426. doi: 10.1172/JCI89587.
4
[Clinical analysis of the fatal cases of adult malignant gliomas after aggressive treatment].[积极治疗后成人恶性胶质瘤致死病例的临床分析]
No Shinkei Geka. 1994 Mar;22(3):207-13.
5
Glioblastoma multiforme: overview of current treatment and future perspectives.多形性胶质母细胞瘤：当前治疗方法概述及未来展望。
Hematol Oncol Clin North Am. 2012 Aug;26(4):825-53. doi: 10.1016/j.hoc.2012.04.006. Epub 2012 May 11.
6
Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.多形性胶质母细胞瘤复发的分子与临床特征综合描述
Oncotarget. 2015 Oct 13;6(31):30968-74. doi: 10.18632/oncotarget.5038.
7
External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma.用于复发性胶质母细胞瘤治疗的外照射再照射、联合放化疗及粒子治疗。
Expert Rev Anticancer Ther. 2016;16(3):347-58. doi: 10.1586/14737140.2016.1143364. Epub 2016 Feb 9.
8
The role of avastin in the management of recurrent glioblastoma.阿瓦斯汀在复发性胶质母细胞瘤治疗中的作用。
Neurosurg Clin N Am. 2012 Apr;23(2):331-41, x. doi: 10.1016/j.nec.2012.02.001. Epub 2012 Feb 25.
9
Brain malignancies: Glioblastoma and brain metastases.脑恶性肿瘤：胶质母细胞瘤和脑转移瘤。
Semin Cancer Biol. 2020 Feb;60:262-273. doi: 10.1016/j.semcancer.2019.10.010. Epub 2019 Oct 22.
10
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.从原发性肿瘤到复发性肿瘤的神经胶质瘤干细胞样细胞的遗传进化。
Stem Cells. 2017 Nov;35(11):2218-2228. doi: 10.1002/stem.2703. Epub 2017 Sep 29.
引用本文的文献
1
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.瑞戈非尼在复发性胶质母细胞瘤老年患者中的临床活性。
Mol Clin Oncol. 2023 Jan 10;18(2):9. doi: 10.3892/mco.2023.2605. eCollection 2023 Feb.
2
Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy.治疗后复发性胶质母细胞瘤患者免疫微环境中源自血液的巨噬细胞持续积聚。
Cancers (Basel). 2021 Dec 7;13(24):6178. doi: 10.3390/cancers13246178.
3
Disproportion in Pericyte/Endothelial Cell Proliferation and Mechanisms of Intussusceptive Angiogenesis Participate in Bizarre Vessel Formation in Glioblastoma.周细胞/内皮细胞增殖失衡及腔内增殖型血管生成的机制参与胶质母细胞瘤奇异血管形成。
Cells. 2021 Oct 1;10(10):2625. doi: 10.3390/cells10102625.
4
Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study.瑞戈非尼用于复发性胶质母细胞瘤患者：一项大型单中心真实世界研究。
Cancers (Basel). 2021 Sep 21;13(18):4731. doi: 10.3390/cancers13184731.
5
Glioblastoma: Emerging Treatments and Novel Trial Designs.胶质母细胞瘤：新兴治疗方法与新型试验设计
Cancers (Basel). 2021 Jul 26;13(15):3750. doi: 10.3390/cancers13153750.
6
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).地帕妥昔单抗莫福汀（Depatux-M）联合替莫唑胺治疗复发性胶质母细胞瘤患者：来自意大利神经肿瘤协会（AINO）多中心研究的真实世界经验
Cancers (Basel). 2021 Jun 3;13(11):2773. doi: 10.3390/cancers13112773.
7
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an -Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRD.免疫检查点抑制作为 CMMRD 患者伴 -突变间变性星形细胞瘤的主要辅助治疗：案例报告——免疫检查点抑制在 CMMRD 中的应用。
Curr Oncol. 2021 Feb 1;28(1):757-766. doi: 10.3390/curroncol28010074.
本文引用的文献
1
The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions.多形性胶质母细胞瘤的新型治疗方法与挑战：现状与未来方向
Pharmaceuticals (Basel). 2020 Nov 14;13(11):389. doi: 10.3390/ph13110389.
2
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study.帕博利珠单抗在错配修复蛋白表达部分或完全缺失的复发性高级别胶质瘤中的活性：一项单中心、观察性前瞻性试点研究。
Cancers (Basel). 2020 Aug 14;12(8):2283. doi: 10.3390/cancers12082283.
3
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.与接受regorafenib 治疗的胶质母细胞瘤患者生存延长相关的分子特征。
Neuro Oncol. 2021 Feb 25;23(2):264-276. doi: 10.1093/neuonc/noaa156.
4
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.磷酸化乙酰辅酶 A 羧化酶与复发胶质母细胞瘤患者接受regorafenib 治疗的临床获益相关：REGOMA 试验的生物标志物分析。
Clin Cancer Res. 2020 Sep 1;26(17):4478-4484. doi: 10.1158/1078-0432.CCR-19-4055. Epub 2020 Jun 9.
5
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.纳武利尤单抗对比贝伐珠单抗治疗复发性胶质母细胞瘤患者的效果：CheckMate 143 期随机临床试验。
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
6
How did lomustine become standard of care in recurrent glioblastoma?洛莫司汀如何成为复发性胶质母细胞瘤的标准治疗方法？
Cancer Treat Rev. 2020 Jul;87:102029. doi: 10.1016/j.ctrv.2020.102029. Epub 2020 May 4.
7
Molecular Evolution of Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.标准治疗下的野生型胶质母细胞瘤的分子进化会影响生存和精准医学试验的设计：来自 EORTC 1542 研究的报告。
J Clin Oncol. 2020 Jan 1;38(1):81-99. doi: 10.1200/JCO.19.00367. Epub 2019 Nov 19.
8
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.美国 2012-2016 年诊断的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150.
9
Molecular targeted therapy of glioblastoma.脑胶质瘤的分子靶向治疗。
Cancer Treat Rev. 2019 Nov;80:101896. doi: 10.1016/j.ctrv.2019.101896. Epub 2019 Sep 11.
10
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review.抗 PD-1/PD-L1 免疫检查点抑制剂在胶质母细胞瘤中的应用：简要综述。
Crit Rev Oncol Hematol. 2019 Mar;135:128-134. doi: 10.1016/j.critrevonc.2018.12.002. Epub 2019 Feb 1.
Zotero 插件